Spravato vs. Ketamine: Understanding the Differences

If you're researching ketamine for depression, you've likely encountered two options that sound similar but work differently in practice: Spravato (esketamine) and racemic ketamine. They're related, they're both used for treatment-resistant depression, and they both involve ketamine-based molecules. But the FDA status, insurance coverage, administration method, and clinical context are different in ways that affect your treatment decisions.

This page breaks down those differences without overselling either option.

Key Facts

• Spravato (esketamine): FDA-approved nasal spray for treatment-resistant depression in adults, used with an oral antidepressant. Must be administered in a certified healthcare setting (REMS program).
• Racemic ketamine: Used off-label for depression, PTSD, and chronic pain. Administered IV or IM in a clinical setting. Not FDA-approved for psychiatric indications.
• Both are Schedule III controlled substances requiring medical supervision
• Key practical difference: Spravato may be partially covered by insurance; racemic ketamine is typically cash-pay

What Is Spravato (Esketamine)?

Spravato is the brand name for esketamine, a nasal spray manufactured by Janssen Pharmaceuticals (a Johnson & Johnson company). It received FDA approval in March 2019 for treatment-resistant depression in adults, and in August 2020 for major depressive disorder with suicidal ideation or behavior, in both cases used in conjunction with an oral antidepressant.

What "esketamine" means chemically: Ketamine is a racemic mixture, meaning it contains two mirror-image molecules: S-ketamine (esketamine) and R-ketamine. Spravato contains only the S-ketamine enantiomer, which has a higher affinity for the NMDA receptor.

How Spravato is administered:

• Self-administered nasal spray under direct supervision of a healthcare provider
• Must be given in a certified healthcare facility enrolled in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program
• Patient must be monitored for at least 2 hours after each dose
• Cannot take the medication home
• Typical induction: twice weekly for 4 weeks, then once weekly for 4 weeks, then once weekly or every 2 weeks ongoing

FDA-required use conditions:

• Must be used in combination with an oral antidepressant
• Patient must be observed for at least 2 hours post-dose
• Cannot drive or operate heavy machinery until the next day
• Only available through certified REMS providers

What Is Racemic Ketamine?

Racemic ketamine contains both the S- and R-ketamine enantiomers. It has been FDA-approved as an anesthetic since 1970 and has been used safely in operating rooms and emergency departments for decades. Its use for depression, PTSD, and chronic pain is off-label, meaning providers prescribe it based on clinical evidence even though the FDA hasn't specifically approved it for these conditions.

Off-label prescribing is legal, common, and accounts for roughly 20% of all prescriptions in the United States. The distinction matters for insurance coverage but not for legality or medical appropriateness.

How racemic ketamine is administered for depression:

• Intravenous (IV) infusion over approximately 40 minutes, or intramuscular (IM) injection
• Administered in a clinical setting with vital sign monitoring
• Induction series: typically 6 sessions over 2-3 weeks
• Maintenance: frequency varies based on individual response (often monthly)
• Some providers also use sublingual or oral ketamine, though these routes have less predictable absorption

Head-to-Head Comparison

Effectiveness: What the Research Says

Both forms of ketamine have demonstrated efficacy for treatment-resistant depression, but the evidence isn't directly comparable because the studies used different designs, doses, and populations.

Spravato efficacy data:

• In the pivotal phase 3 trial (Popova et al., 2019), Spravato + oral antidepressant produced a statistically significant reduction in depression scores compared to placebo nasal spray + oral antidepressant at week 4.
• A relapse-prevention trial (Daly et al., 2019) found that patients who responded to Spravato had lower relapse rates when continuing treatment compared to those who switched to placebo.
• Response rates in clinical trials were approximately 65-70%, with remission rates around 30-40%.

Racemic ketamine efficacy data:

• A 2013 RCT by Murrough et al. in The American Journal of Psychiatry found that a single IV ketamine infusion produced rapid antidepressant effects within 24 hours, with response rates of approximately 64% at 24 hours.
• Multiple meta-analyses confirm short-term antidepressant efficacy, though optimal long-term dosing protocols are still being established.
• Some clinicians and researchers argue that racemic ketamine's inclusion of R-ketamine may provide additional therapeutic benefit, though this remains debated.

The honest assessment: Both work for a meaningful percentage of TRD patients. Neither works for everyone. The choice between them is often driven by practical factors, specifically insurance coverage, access, and provider availability, rather than clear-cut superiority of one over the other.

Insurance and Cost Considerations

This is often the deciding factor.

Spravato insurance coverage:

• Because Spravato is FDA-approved for TRD, many commercial insurance plans and some Medicare Advantage plans cover it, typically after prior authorization demonstrating that the patient has failed at least two antidepressants.
• Coverage varies significantly by plan. Some cover it fully after deductible; others require high copays.
• Janssen offers a savings program for commercially insured patients.
• Even with coverage, the REMS requirements (certified facility, 2-hour monitoring) create logistical and cost overhead.

Racemic ketamine insurance:

• Because racemic ketamine for depression is off-label, most insurance plans do not cover it.
• Patients typically pay cash, which in Florida ranges from approximately $400-800 per session depending on the provider.
• A full induction series (6 sessions) costs approximately $2,400-4,800 out of pocket.
• Some providers offer payment plans or accept medical financing (CareCredit, Cherry, etc.).

If insurance coverage is a primary factor and you have a TRD diagnosis, Spravato may be the more accessible option. If you're paying cash regardless, or if your condition includes PTSD or chronic pain (which Spravato is not indicated for), racemic ketamine may be the better fit.

How to Decide Between Them

There's no universal "better" option. The right choice depends on your clinical situation:

Spravato may be better if:

• You have treatment-resistant depression (the specific FDA-approved indication)
• Your insurance covers it or you can access the Janssen savings program
• You prefer nasal spray over IV/IM
• You want the reassurance of an FDA-approved indication

Racemic ketamine may be better if:

• You have PTSD, chronic pain, or depression outside the strict TRD definition
• You're paying cash anyway and want potentially lower per-session costs
• Your provider has extensive experience with IV ketamine protocols
• You prefer IV/IM administration (more predictable absorption)

Either way:

• Both require medical supervision
• Both are Schedule III controlled substances
• Both have similar side effect profiles (dissociation, nausea, blood pressure elevation)
• Neither is a standalone treatment; ongoing psychiatric care is essential
• Neither is a cure for depression

How Ascend Can Help

At Ascend Mind and Body, Anna Stouffer, PMHNP provides ketamine therapy and psychiatric evaluations that help you determine which option aligns with your diagnosis, treatment history, and financial situation.

Your consultation includes a review of your medication history, depression severity, and insurance coverage. We discuss both options honestly, including what each can and cannot do, and we help you make an informed decision.

For patients with treatment-resistant depression who qualify for Spravato, we can evaluate coverage options. For patients with PTSD or chronic pain, or those paying cash, racemic ketamine is the appropriate pathway.

Anna is in-network with Aetna, Cigna, UnitedHealthcare, Medicare, Medicaid, TRICARE, AARP, and ChampVA for psychiatric evaluation. Ketamine therapy pricing is discussed transparently during your consultation. Visit our new patients page to schedule.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment.